🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Most #ALS cases have no known cause, making treatment challenging. With CIRM support, Julia Kaye, PhD, at Gladstone Institutes is using patient-derived stem cells to model ALS and uncover new therapeutic targets. #StemCellResearch #RegenerativeMedicine blog.cirm.ca.gov/2025/03/27/how…

In this profile, the California Institute for Regenerative Medicine (@cirmnews), feature Gladstone scientist Julia Kaye and her ALS research. bit.ly/43AVaRm

For 20 years, CIRM has helped transform regenerative medicine—funding research, training scientists, and advancing over 110 clinical trials. From early barriers to life-changing therapies, the impact is clear. #RegenerativeMedicine #California #StemCells blog.cirm.ca.gov/2025/04/03/20-…

Neurona Therapeutics was highlighted in Endpoints News for its advancements on NRTX-1001, a first-in-class cell therapy for drug-resistant #epilepsy. CIRM has supported this initiative from #discovery through #ClinicalTrials, including a recent grant of $14M. endpts.com/exclusive-neur…

CIRM is supporting #Neuroscience research through funding programs like ReMIND and DISC4. We are committed to bridging critical funding gaps and accelerating the development of transformative therapies for #CNSdisorders and #diseases. blog.cirm.ca.gov/2025/04/09/fil…

CIRM is excited to announce our new funding opportunity, the DISC4 Awards! This funding program supports collaborative, cross-disciplinary research in California. Visit our website to learn about the DISC4 Awards and sign up for email updates at cirm.ca.gov/disc4/

In 2007, Justin had his first epileptic seizure. Years later, he joined a CIRM-funded trial led by Neurona Therapeutics at UC San Diego Health for a #StemCellTherapy known as NRTX-1001. Since treatment, his symptoms have significantly improved. blog.cirm.ca.gov/2025/04/16/div…

Cook MyoSite’s cell therapy, now being evaluated at UC Davis Health, uses a patient’s own muscle stem cells to help head and neck cancer patients with swallowing difficulties. The therapy received U.S. FDA RMAT status and is supported by an $11M CIRM grant. health.ucdavis.edu/news/headlines…

CIRM has awarded nearly $8 million to Ray Therapeutics, Inc. to support a Phase 1 clinical trial for retinitis pigmentosa (RP), a rare, degenerative eye disease with no cure. This marks the 116th CIRM-funded clinical trial. cirm.ca.gov/about-cirm/new…

April is #ParkinsonsAwarenessMonth. CIRM awarded NysnoBio $2.5M for a #GeneTherapy approach targeting Parkin gene mutations that cause early-onset #Parkinsons. The goal is to restore protein function and improve mitochondrial health. Read full blog: blog.cirm.ca.gov/2025/04/25/new…

We were honored to join the Parkinson's Foundation #Moving4PD event in SF over the weekend! With 300+ attendees, dance warmups, and our trivia wheel spinning, it was a great way to share how CIRM is supporting Parkinson’s research. #ParkinsonsAwareness #CIRM #StemCells

Congratulations to the USC Stem Cell CIRM COMPASS Program on hosting its first year-end symposium! We're proud to support this comprehensive two-year program, which prepares undergraduates for careers in stem cell biology and regenerative medicine. 🎉 stemcell.keck.usc.edu/guided-by-comp…

Thank you for hosting this inspiring conversation with our Chief Science Officer, Dr. Canet-Avilés. We’re proud to support transformative science and grateful to collaborate with dedicated leaders like you!

Since 2007, CIRM has funded early research from USC that developed a #StemCellTherapy for age-related #MacularDegeneration (AMD), a leading cause of #blindness worldwide. Now, that project has advanced to the #ClinicalTrials stage. #DiscoveryResearch blog.cirm.ca.gov/2025/05/12/20-…

CIRM is now on BlueSky! Follow us for updates on stem cell and gene therapy research, CIRM-funded clinical trials, and the latest breakthroughs in regenerative medicine. bsky.app/profile/cirmne… #RegenerativeMedicine #BlueSky

CIRM is excited to announce our new funding opportunities, the Preclinical Development (PDEV) and Clinical Trial (CLIN2) Awards! Learn more about both funding programs on our website at cirm.ca.gov/researchers/fu…

CIRM's new funding program, the DISC4 Awards, is designed to support large, cross-disciplinary research teams advancing innovative approaches to understand and treat human disease. Learn more about the DISC4 Awards and sign up for email updates at cirm.ca.gov/disc4/.

The Preclinical Development (PDEV) Awards accelerate the development of stem cell & genetic therapies. This funding supports preclinical work, from candidate optimization to FDA IND clearance, helping researchers bring treatments to patients. Learn more: cirm.ca.gov/preclinical/

CIRM was proud to participate in Stanford’s iWISH Talks, where our Chief Science Officer, Dr. Rosa Canet-Avilés shared her journey across neuroscience, stem cell science, and leadership. Thank you @stanfordCVI for hosting!

CIRM’s Clinical Trial (CLIN2) Awards accelerate the development of regenerative medicine therapies for serious unmet medical needs. Our goal is to help these therapies progress toward FDA approval, improving patient care in California. Learn more at cirm.ca.gov/clinical/